Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

The androgen receptor remains front and centre

Nature Reviews Clinical Oncology volume 10, pages 126–128 (2013)Cite this article

Subjects

Abiraterone is an androgen biosynthesis inhibitor that further lowers testosterone in men receiving standard androgen deprivation therapy for metastatic castration-resistant prostate cancer. Previously shown to improve survival in patients after treatment with docetaxel, abiraterone has demonstrated benefits in a new phase III trial in men who are chemotherapy naive.

Key Points

  • Abiraterone has been shown in two distinct phase III trials to benefit men with metastatic castration-resistant prostate cancer

  • The efficacy and relative tolerability of abiraterone argue for its use prior to chemotherapy in this patient population

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).

    Article  CAS  PubMed  Google Scholar 

  3. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

    Article  CAS  PubMed  Google Scholar 

  4. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).

    Article  CAS  PubMed  Google Scholar 

  5. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    CAS  PubMed  Google Scholar 

  6. Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019–6029 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992–8002 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Smith, M. R. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin. Cancer Res. 13, 241–245 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Saylor, P. J. & Smith, M. R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 181, 1998–2008 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

P. J. Saylor is supported by a Young Investigator Award from the Prostate Cancer Foundation.

Author information

Authors and Affiliations

  1. Division of Hematology–Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7E, Boston, 02114, MA, USA

    Philip J. Saylor

Authors
  1. Philip J. Saylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saylor, P. The androgen receptor remains front and centre. Nat Rev Clin Oncol 10, 126–128 (2013). https://doi.org/10.1038/nrclinonc.2013.14

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.14

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing